Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Merck’s CV Pipeline: A Shrinking But Strident Commitment

Aug 13 2012

• By Lisa LaMotta

Related Content

Phase III Setback For Merck's Antithrombotic Damages One Of The Key Assets Of The Schering Merger

Jan 13 2011

More Disheartening News For Abbott Cholesterol Franchise: Niaspan/Statin Study Halted Due To Lack Of Added Benefit

May 26 2011

Dalcetrapib Failure Raises Yet More Questions On Value Of Tinkering With HDL Cholesterol

May 14 2012

Merck Drops Zocor Combo, But Keeps Going With <em>Tredaptive</em>

Aug 09 2012

Merck CEO To Street: Watch For Short-term Adaptability, Long-Term Innovation

Jan 05 2012

The SHARP “Approval”: Merck Gets <em>Vytorin</em> Labeling Change, But Not The CV Outcomes Claim It Sought

Feb 13 2012

Merck Drops Development Of Cardiome’s Oral Vernakalant

Mar 20 2012

Pfizer’s Lipitor Extension Shot Down By Failure Of Torcetrapib Silver Bullet

Dec 11 2006

Branded Life After <em>Lipitor</em>: Pharma Targets Unmet Needs In Dyslipidemia

Apr 23 2012

Back To The Drawing Board For Portola After Merck Returns Betrixaban

Mar 24 2011

Bleeding Rates In TRA-2P Further Dim Outlook For Merck’s Vorapaxar

Apr 01 2012

Related Companies

Pfizer Inc.

Abbott

Roche Holding AG

Eli Lilly and Company

Portola Pharmaceuticals, Inc.

Cardiome Pharma Corp.

Additional Topics

Clinical Trials Regulation BioPharmaceutical

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window